The prevalence of proton pump inhibitor use in hospitalized patients

Practical Gastroenterology

Volumn 30, Issue 5, 2006, Pages 24-34

  Gingold, Alan R ^a   Narasimhan, Gopal ^a   Augello, Sabino ^a   Clain, David J ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; DRUG USE; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITAL PATIENT; HUMAN; INTERDISCIPLINARY EDUCATION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PROPHYLAXIS; RESIDENT; REVIEW; TREATMENT INDICATION;

EID: 33744928934     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Noguerado AA, Rodriguez BR, Zelaya CP, et al. Use of acid-suppressive medications in hospitalized patients. An Med Interna, 2002;19:555-556.
2. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Therapeutics, 2000;25:333-340.
3. Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci, 2001;23:116-117.
4. Pillans PI, Kubler PA, Radford JM, et al. Concordance between use of proton pump inhibitors and prescribing guidelines. Med J Aust, 2000;172:16-18.
5. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol, 2000;95: 3118-3122.
6. Parente F, Cucino C, Gallus S, et al. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther, 2003;17:1503-1506.
7. Guda NM, Noonan M, Kreiner MJ, et al. Use of intravenous proton pump inhibitors in community practice: an explanation for the shortage? Am J Gastroenterol, 2004;99:1233-1237.
8. Kaplan GG, Bates D, McDonald D, et al. Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions. Clin Gastroenterol Hepatol, 2005;3:1207-1214.
9. Zink DA, Pohlman M, Barnes M, Cannon ME. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther, 2005;21:1203-1209.
10. Der G. An overview of proton pump inhibitors. Gastroenterol Nurs, 2003;26:182-190.
11. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. NEJM, 1994;330:377-381.
12. Steinberg KP. Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit. Crit Care Med, 2002;30:S362-S364.
13. Cash BD. Evidence-based medicine as it applies to acid suppression in the hospitalized patient. Crit Care Med, 2002;30:S373-S378.
14. Lam NP, Le, PDT, Crawford, et al. National survey of stress ulcer prophylaxis. Crit Care Med, 1999;27:98-103.
15. Goldstein JL. Who needs prophylaxis of nonsteroidal anti-inflammatory drug-induced ulcers and what is optimal prophylaxis? Eur J Gastroenterol Hep, 2000; 12:S11-S15.
16. Arlt GD, Leyh M. Incidence and pathophysiology of peptic ulcer bleeding. Langenbecks Arch Surg, 2001;386:75-81.
17. Lamers CB, Biemond I, Masclee AA, et al. Therapy and prevention of gastric ulcer. Yale J Bio Med, 1996;69:265-270.
18. Ellershaw JE, Kelly MJ. Corticosteroids and peptic ulceration. Palliative Med, 1994;8:313-319.
19. Winiarski M, Biesiada Z, Rembiasz K, et al. Incidence and risk factors of rebleeding from gastric and duodenal ulcers. Przegl Lek, 2003;60:S7-S12.
20. Holtmann G, Howden CW. Management of peptic ulcer bleeding-the roles of proton pump inhibitors and Helicobacter pylori eradication. Aliment Pharmacol Ther, 2004;19:S66-S77.
21. Long D. 2003 U.S. Pharmaceutical Market. Trends, Issues, Forecasts. IMS Health: National Sales Perspective August, 2003.